Menu

Pipeline Overview*

Pipeline Overview*

Drug** Indication Pre-clinical Phase 1/2 Phase 3 Approved
Talicia® H. pylori infection***
Approved by U.S. FDA November 2019
RHB-104 Crohn's disease
Positive top-line results from Phase 3 MAP US study
RHB-204 NTM infections
Pivotal Phase 3 study planned
RHB-102
(Bekinda®)
Gastroenteritis & gastritis
Positive results from Phase 3 U.S. study
IBS-D
Positive results from Phase 2 U.S. study
RHB-106 Bowel cleanser
WW rights licensed to Salix Pharmaceuticals
ABC294640
(Yeliva®)
Multiple indications
Cholangiocarcinoma and other indications
RHB-107 Oncology/GI
Completed multiple clinical studies
Other
RIZAPORT®
(RHB-103)
Migraine
U.S. NDA filed - re-submission of NDA planned following CRL
EUROPEAN MAA APPROVED UNDER THE EUROPEAN DECENTRALIZED PROCEDURE
* Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies**Bekinda® (RHB-102) and Yeliva® (ABC294640) are proposed tradenames which are subject to FDA review and approval. ***Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: here